Table 1 |
||||
| Demographic factors and filled prescription data in cases with advanced gastric cancer (AGC) and matched controls | ||||
| Variables | AGC (n=983) | Control (n=983) | ||
| N | % | N | % | |
| Mean age, y | 62.6 | 62.6 | ||
| Sex | ||||
| Men | 752 | 76.5 | 752 | 76.5 |
| Women | 231 | 23.5 | 231 | 23.5 |
| Statin user | 99 | 10.1 | 367 | 37.3 |
| Atorvastatin | 31 | 31.3 | 143 | 39.0 |
| Simvastatin | 27 | 27.3 | 67 | 18.2 |
| Rosuvastatin | 11 | 11.1 | 59 | 16.1 |
| Pravastatin | 12 | 12.1 | 48 | 13.1 |
| Pitavastatin | 4 | 4.0 | 18 | 4.9 |
| Others | 14 | 14.1 | 32 | 8.7 |
| Statin exposure duration (year) | ||||
| 0 - < 0.5 | 884 | 89.9 | 616 | 62.7 |
| 0.5 – 1.0 | 38 | 3.9 | 71 | 7.2 |
| 1.0 – 1.5 | 12 | 1.2 | 61 | 6.2 |
| 1.5 – 2.0 | 13 | 1.3 | 41 | 4.2 |
| >2.0 | 36 | 3.7 | 194 | 19.7 |
| Aspirin | ||||
| Yes | 184 | 18.7 | 347 | 35.3 |
Lee et al. BMC Cancer 2012 12:596 doi:10.1186/1471-2407-12-596
